Does vascepa's patented formula increase its price?

Question

Accepted Answer

Short answer

Yes – the patent protection on Vascepa’s active ingredient (icosapent ethyl) and on certain aspects of its formulation has helped keep the drug’s U.S. price high, but it’s not the only factor. The price is also driven by the drug’s research‑and‑development (R&D) costs, the size of the patient population, manufacturing complexity, and the pricing practices of the pharmaceutical industry.

1. What’s in a patent?

Patent element	What it protects	How it can affect price
Chemical composition (icosapent ethyl)	The active molecule itself	Keeps generic competitors out of the market until the patent expires.
Manufacturing process	The specific method to produce the drug in a stable, purified form	Prevents others from making cheaper versions that might have stability or purity issues.
Formulation & dosage	The final product (e.g., 1 g capsules, 3‑g daily dose)	Limits other companies from offering a cheaper pill that’s still clinically equivalent.

When a patent expires, generic manufacturers can apply for FDA approval, which usually leads to a sharp drop in price. For Vascepa, the chemical‑composition patent expired in 2021, but the company has other patents (e.g., on the 1‑g capsule formulation and on certain manufacturing processes) that still give it market exclusivity. Those secondary patents can delay generics and keep prices high.

2. Other drivers of the high price

Factor	How it contributes
R&D costs	The clinical trials for Vascepa (e.g., the REDUCE‑IT study) cost billions of dollars. Companies recoup these costs through higher pricing.
Manufacturing complexity	icosapent ethyl is a purified form of EPA. Its synthesis requires strict control of isomerization and impurities, which raises production costs.
Patient population	Vascepa is prescribed for a relatively small group of patients (those with very high triglycerides despite statins). With fewer patients, the company charges more per prescription to break even.
Marketing & promotion	Significant investment in marketing to clinicians and patients can be reflected in the list price.
Insurance & reimbursement	The U.S. payer landscape often sets a “reference price” that influences how much a drug is sold for. High list prices can drive higher rebates and discounts, but the starting point remains high.

3. What happens after the patent expires?

Generic entry: Once all critical patents expire, other companies can submit Abbreviated New Drug Applications (ANDAs) for a generic version. The first generic usually enters the market 6–12 months after approval.
Price drop: In many cases, the price can fall by 60–90 % once a generic is available. For Vascepa, the first generic approvals in the U.S. were expected in late 2024–2025; early reports suggest a 70–80 % price reduction.
Brand‑name persistence: Even after generic entry, some patients and clinicians may prefer the brand‑name product because of brand recognition or perceived reliability.

4. Bottom line

Patents do contribute to the high price, as they give the manufacturer exclusivity and prevent lower‑cost competitors from entering the market for a time.
But they’re only one piece of a larger puzzle that includes R&D recoupment, manufacturing costs, patient population size, and pricing strategies.
When the patents finally expire, you can expect a significant price drop, which may make Vascepa more affordable for patients who need it.

If you’re concerned about the cost of your medication, talk to your pharmacist or prescriber—they may know about discount programs or upcoming generic alternatives that could lower your out‑of‑pocket expense.

Ask Questions, Get Industry Insights … Instantly

Recent Questions

Does vascepa's patented formula increase its price?

Short answer

1. What’s in a patent?

2. Other drivers of the high price

3. What happens after the patent expires?

4. Bottom line